Cancer Stem Cell News Volume 3.33 | Aug 27 2014

Cancer Stem Cell News 3.33 August 27, 2014

Cancer Stem Cell News

     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CSCN on Twitter

Treating Cancer with Botox
Researchers show that the vagal nerve contributes to the growth of gastric tumors, so that stopping the nerve signal to the tumor will stop its growth. They show that cancer growth could be suppressed by eliminating the signals sent by nerves that are linked to cancer stem cells. The use of Botox made the treatment cheap, safe and efficient. [Press release from Norwegian University of Science and Technology discussing online prepublication in Science Translational Medicine] Press Release | Abstract
[Watch the Video] Detect Cancer Stem Cells with ALDEFLUOR™

PUBLICATIONS (Ranked by impact factor of the journal)
EGFR Blockade Enriches for Lung Cancer Stem-Like Cells through Notch3-Dependent Signaling
The authors report that treatment of epidermal growth factor receptor (EGFR)-mutated lung cancer cell lines with erlotinib, while showing robust cell death, enriches the ALDH+ stem-like cells through EGFR-dependent activation of Notch3. [Cancer Res] Abstract | Full Article

VEGF Drives Cancer-Initiating Stem Cells through VEGFR-2/Stat3 Signaling to Upregulate Myc and Sox2
Investigators show vascular endothelial growth factor-A (VEGF) promotes breast and lung cancer stem cell self-renewal via VEGF receptor-2 (VEGFR-2)/STAT3-mediated upregulation of Myc and Sox2. [Oncogene] Abstract

Peritoneal Milky Spots Serve as a Hypoxic Niche and Favor Gastric Cancer Stem/Progenitor Cell Peritoneal Dissemination through Hypoxia-Inducible Factor 1α
Researchers investigated whether hypoxic peritoneal milky spots were an ideal cancer stem cell niche suitable for gastric cancer stem/progenitor cells (GCSPCs) engraftment. They also evaluated the mechanisms through which the hypoxia-inducible factor 1α-mediated hypoxic microenvironment regulated GCSPC fate. [Stem Cells] Abstract

Periostin Is a Novel Therapeutic Target that Predicts and Regulates Glioma Malignancy
Periostin is a secreted matricellular protein critical for epithelial-mesenchymal transition and carcinoma metastasis. Functional assays determined the impact of altering periostin expression and function on cell invasion, migration, adhesion, and glioma stem cell activity and tumorigenicity. [Neuro Oncol] Abstract

Sialidase NEU4 Is Involved in Glioblastoma Stem Cell Survival
Scientists demonstrate that glioblastoma stem cells isolated from glioblastoma multiforme (GBM) cell lines and patients’ specimens as neurospheres are specifically marked by the upregulation of NEU4; in contrast, the expression of NEU4 is very low in non-neurosphere-differentiated GBM cells. [Cell Death Dis]
Full Article | Press Release

The Impact of Inflammatory Lipid Mediators on Colon Cancer-Initiating Cells
The role of inflammatory lipid-mediators in tumor progression is well recognized in colorectal cancer; however, if this includes promotion of cancer-initiating cells remains unclear. Investigators show that the inflammatory lipid-mediators leukotriene D4 and prostaglandin E2 increased the aldehyde dehydrogenase population, the colony formation capacity, and tumor growth in a xenograft model of colon cancer. [Mol Carcinog] Abstract

ER-α Variant ER-α36 Mediates Antiestrogen Resistance in ER-Positive Breast Cancer Stem/Progenitor Cells
Scientists investigated the function and the underlying mechanism of ER-α36-mediated antiestrogen signaling in ER-positive breast cancer stem/progenitor cells. The effects of antiestrogens tamoxifen and ICI 182, 780 on breast cancer stem cells’ ability of growth, self-renewal, differentiation and tumor seeding were examined using tumorsphere formation, flow cytometry, indirect immunofluorences and in vivo xenograft assays. [J Steroid Biochem Mol Biol] Abstract

Chemo-Predictive Assay for Targeting Cancer Stem-Like Cells in Patients Affected by Brain Tumors
Researchers developed an ex vivo chemotherapy sensitivity assay which measures the sensitivity of cancer stem-like cells as well as the bulk of tumor cells to a variety of chemotherapy agents. [PLoS One] Full Article

Prostate Cancer Stem-Like Cells Proliferate Slowly and Resist Etoposide-Induced Cytotoxicity via Enhancing DNA Damage Response
Researchers demonstrate that DU145-derived prostate cancer stem cells (PCSCs) progress slowly with more cells accumulating in the G1 phase in comparison to DU145 non-PCSCs. In response to etoposide (one of the most commonly used chemotherapeutic drugs), DU145 PCSCs survived significantly better than non-PCSCs. [Exp Cell Res] Abstract

Targeting Melanocyte and Melanoma Stem Cells by 8-Hydroxy-2-Dipropylaminotetralin
Monobenzyl ether of hydroquinone (MBEH) is cytotoxic towards melanocytes. Its treatment efficacy is limited by an inability to eradicate stem cells. By contrast, 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-DPAT) affects melanocyte stem cell survival. MBEH and 8-DPAT were added to melanocytes and melanoma cells to compare cytotoxicity. [Arch Biochem Biophys] Abstract

NeuroCult™ for Brain Tumor Research - View Publications

Implications of Stemness-Related Signaling Pathways in Breast Cancer Response to Therapy
There is accumulating evidence that breast cancer may arise from a small subpopulation of transformed mammary stem/progenitor cells responsible for initiation and maintenance of cancer. Alterations in genes involved in stemness-related pathways, such as Wnt, Notch, and Sonic Hedgehog, have been proven to play a role in breast cancer progression. [Semin Cancer Biol] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Herbert Irving Comprehensive Cancer Center Has Designation Renewed by National Cancer Institute; Awarded $18 Million Grant
Outstanding basic research, a growing focus on translating discoveries into treatments, and a dedication to patient care have earned the Herbert Irving Comprehensive Cancer Center of Columbia University Medical Center and New York-Presbyterian Hospital an $18 million, five-year Cancer Center Support Grant from the National Cancer Institute. [Columbia University Medical Center] Press Release

Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer
Advaxis, Inc. has entered into a clinical trial collaboration agreement with Merck to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck’s investigational anti PD-1 antibody, pembrolizumab. [Advaxis, Inc.] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Global Cancer Conference & Medicare Summit 2014
September 15-17, 2014
Hyderabad, India

NEW 2nd International Symposium on Advances in Circulating Tumor Cells (ACTC)
October 8-11, 2014
Crete, Greece

NEW New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures
October 9-12, 2014
Shanghai, China

Visit our events page to see a complete list of events in the cancer stem cell community.

NEW PhD Position – Breast Cancer Stem Cells (University of Copenhagen)

NEW Postdoctoral Fellow – Cancer Cell Survival and Proliferation (Washington State University)

Postdoctoral Position – Stem Cell Biology/Cancer Biology (Oregon Health & Science University)

Postdoctoral Research Fellow – Induced Pluripotent Stem Cell Based Therapeutics (Fred Hutchinson Cancer Research Center)

Tenure Track Positions – Cancer Biology (Wake Forest Baptist Medical Center)

Technical Account Manager (GlobalStem)

Postdoctoral Position – Molecular Properties of Leukemic Stem Cells (BC Cancer Agency)

Postdoctoral Research Associate – Cancer Stem Cell Biology (University of California, San Diego)

Postdoctoral Fellowships – Cancer Research (German Cancer Research Center [DKFZ])

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here

Learn more about Cancer Stem Cell News: Archives | Events | Contact Us